Literature DB >> 10338503

Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family.

D C Dillon1, M R Alderson, C H Day, D M Lewinsohn, R Coler, T Bement, A Campos-Neto, Y A Skeiky, I M Orme, A Roberts, S Steen, W Dalemans, R Badaro, S G Reed.   

Abstract

We have used expression screening of a genomic Mycobacterium tuberculosis library with tuberculosis (TB) patient sera to identify novel genes that may be used diagnostically or in the development of a TB vaccine. Using this strategy, we have cloned a novel gene, termed mtb39a, that encodes a 39-kDa protein. Molecular characterization revealed that mtb39a is a member of a family of three highly related genes that are conserved among strains of M. tuberculosis and Mycobacterium bovis BCG but not in other mycobacterial species tested. Immunoblot analysis demonstrated the presence of Mtb39A in M. tuberculosis lysate but not in culture filtrate proteins (CFP), indicating that it is not a secreted antigen. This conclusion is strengthened by the observation that a human T-cell clone specific for purified recombinant Mtb39A protein recognized autologous dendritic cells infected with TB or pulsed with purified protein derivative (PPD) but did not respond to M. tuberculosis CFP. Purified recombinant Mtb39A elicited strong T-cell proliferative and gamma interferon responses in peripheral blood mononuclear cells from 9 of 12 PPD-positive individuals tested, and overlapping peptides were used to identify a minimum of 10 distinct T-cell epitopes. Additionally, mice immunized with mtb39a DNA have shown increased protection from M. tuberculosis challenge, as indicated by a reduction of bacterial load. The human T-cell responses and initial animal studies provide support for further evaluation of this antigen as a possible component of a subunit vaccine for M.tuberculosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10338503      PMCID: PMC96604          DOI: 10.1128/IAI.67.6.2941-2950.1999

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  40 in total

1.  BCG vaccination after the Madras study.

Authors: 
Journal:  Lancet       Date:  1981-02-07       Impact factor: 79.321

2.  The safety of Bacille Calmette-Guérin vaccination in HIV infection and AIDS.

Authors:  A C Weltman; D N Rose
Journal:  AIDS       Date:  1993-02       Impact factor: 4.177

3.  A simple method for displaying the hydropathic character of a protein.

Authors:  J Kyte; R F Doolittle
Journal:  J Mol Biol       Date:  1982-05-05       Impact factor: 5.469

4.  Adoptive protection of the Mycobacterium tuberculosis-infected lung. Dissociation between cells that passively transfer protective immunity and those that transfer delayed-type hypersensitivity to tuberculin.

Authors:  I M Orme; F M Collins
Journal:  Cell Immunol       Date:  1984-03       Impact factor: 4.868

5.  Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature.

Authors:  G A Colditz; T F Brewer; C S Berkey; M E Wilson; E Burdick; H V Fineberg; F Mosteller
Journal:  JAMA       Date:  1994-03-02       Impact factor: 56.272

Review 6.  Tuberculosis in the 1990s.

Authors:  P F Barnes; S A Barrows
Journal:  Ann Intern Med       Date:  1993-09-01       Impact factor: 25.391

7.  Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins.

Authors:  P Andersen
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

8.  Isolation of a proline-rich mycobacterial protein eliciting delayed-type hypersensitivity reactions only in guinea pigs immunized with living mycobacteria.

Authors:  F Romain; J Augier; P Pescher; G Marchal
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

9.  Disseminated tuberculosis in interferon gamma gene-disrupted mice.

Authors:  A M Cooper; D K Dalton; T A Stewart; J P Griffin; D G Russell; I M Orme
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

10.  An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection.

Authors:  J L Flynn; J Chan; K J Triebold; D K Dalton; T A Stewart; B R Bloom
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

View more
  54 in total

1.  Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6.

Authors:  A Weinrich Olsen; L A van Pinxteren; L Meng Okkels; P Birk Rasmussen; P Andersen
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

2.  PPE protein (Rv3873) from DNA segment RD1 of Mycobacterium tuberculosis: strong recognition of both specific T-cell epitopes and epitopes conserved within the PPE family.

Authors:  Limei Meng Okkels; Inger Brock; Frank Follmann; Else Marie Agger; Sandra M Arend; Tom H M Ottenhoff; Fredrik Oftung; Ida Rosenkrands; Peter Andersen
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

Review 3.  On the use of DNA vaccines for the prophylaxis of mycobacterial diseases.

Authors:  Kris Huygen
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

4.  Expression cloning of gamma interferon-inducing antigens of Mycobacterium avium subsp. paratuberculosis.

Authors:  Reiko Nagata; Yoshihiro Muneta; Kazuhiro Yoshihara; Yuichi Yokomizo; Yasuyuki Mori
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

Review 5.  Expression library immunization: a road map for discovery of vaccines against infectious diseases.

Authors:  Adel M Talaat; Katherine Stemke-Hale
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

6.  Association of strong immune responses to PPE protein Rv1168c with active tuberculosis.

Authors:  Nooruddin Khan; Kaiser Alam; Shiny Nair; Vijaya Lakshmi Valluri; Kolluri J R Murthy; Sangita Mukhopadhyay
Journal:  Clin Vaccine Immunol       Date:  2008-04-09

7.  Immunogenicity of the Mycobacterium tuberculosis PPE55 (Rv3347c) protein during incipient and clinical tuberculosis.

Authors:  Krishna K Singh; Yuxin Dong; Sai A Patibandla; David N McMurray; Vijay K Arora; Suman Laal
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

8.  Immune responses to mycobacterial antigens in the Gambian population: implications for vaccines and immunodiagnostic test design.

Authors:  Johan Vekemans; Martin O C Ota; Jackson Sillah; Katherine Fielding; Mark R Alderson; Yasir A W Skeiky; Wilfried Dalemans; Keith P W J McAdam; Christian Lienhardt; Arnaud Marchant
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

9.  Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys.

Authors:  Steven G Reed; Rhea N Coler; Wilfried Dalemans; Wilifred Dalemans; Esterlina V Tan; Eduardo C DeLa Cruz; Randall J Basaraba; Ian M Orme; Yasir A W Skeiky; Mark R Alderson; Karen D Cowgill; Jean-Paul Prieels; Rodolfo M Abalos; Marie-Claude Dubois; Joe Cohen; Pascal Mettens; Yves Lobet
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-02       Impact factor: 11.205

10.  Using epitope predictions to evaluate efficacy and population coverage of the Mtb72f vaccine for tuberculosis.

Authors:  Lucy A McNamara; Yongqun He; Zhenhua Yang
Journal:  BMC Immunol       Date:  2010-03-30       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.